Ranbaxy Laboratories has received final approval from the US Food and Drug Administration to manufacture and market the generic version of Pfizer's Zyrtec (Cetirizine Hydrochloride tablets).
The total annual sale of Cetirizine Hydrochloride tablets, as a prescription-only product, was $1.3 billion (IMS - MAT: September 2007).
Cetirizine Hydrochloride is indicated for temporary relief of runny nose, sneezing, itching of the nose or throat, and itchy, watery eyes due to hay fever or other upper respiratory allergies.
"We are pleased to receive this final approval for Cetirizine Hydrochloride tablets. This OTC product formulation further expands our portfolio of affordable generic alternatives, and will be launched immediately to all classes of trade," said Jim Meehan, vice president (sales and distribution), Ohm Laboratories Inc, a wholly-owned subsidiary of Ranbaxy.
No comments:
Post a Comment